Dr Matthew Matasar speaks to ecancer about polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (POLA-R-GEMOX) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from the randomized phase III POLARGO trial.

The POLARGO trial at EHA 2025 compares polatuzumab vedotin plus R-GemOx or R-GemOx alone for treating relapse or refractory large cell lymphoma.

It involves 255 patients and shows a 40% lower risk of death, improving overall survival from 12 to 19 months.

The study highlights the clinical significance of polatuzumab vedotin and presents the POLA-R-GEMOX regimen as a promising option that preserves future CAR T cell therapy outcomes.